Remember me
Keywords: Total knee arthroplasty, Prosthetic joint infection, Vancomycin, Ceftazidime
Abstract Background Prosthetic joint infection (PJI) is a very disastrous complication of total knee arthroplasty (TKA). Some studies have considered intra-articular antibiotic injection to be effective in the prevention of PJI, but several articles have the opposite opinion. However, there is no study performed in one center, by one surgeon, one surgical team, or one type of prosthetic device. Methods This study was a historical cohort study on the patients who underwent primary TKA with vancomycin and ceftazidime (652 cases from September 2019 to the end of December 2020) that were compared with a cohort of patients with the same TKA method without antibiotics injection (620 controls, from March 2018 to the end of August 2019). The incidence of PJI was followed for 2 years in each group by chart review. Results Study groups were matched for age (P-value=0.193), gender (P-value=0.913), body mass index (P-value=0.136), and radiologic features of their knees (P-value> 0.05). In the case and control groups, one (0.18%) and two (0.32%) patients had PJI, respectively (P-value=0.615). All patients experiencing PJI were subjected to Debridement, antibiotics, implant retention (DAIR) surgery, and antibiotic therapy which responded to the treatment. Conclusion To our knowledge, this is the most precisely matched cohort of TKA subjects in this era. Intra-articular injection of vancomycin and ceftazidime during total knee arthroplasty in the case group showed no significant difference concerning decreasing PJI risk; while for such a rare event of PJI, a study with even larger sample sizes is needed, prospectively.
How to Cite
Ayati Firoozabadi, M., Mortazavi, S. M. J., & Basim Abdan, A. (2023). Efficacy of intra-articular injection of vancomycin and ceftazidime during total knee arthroplasty: prophylaxis of prosthetic joint infection. Galen Medical Journal, 12, e2976. https://doi.org/10.31661/gmj.v12i.2976
Copyright (c) 2023 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Comments (0)